CD19 x CD3
Assets acting on this target.
- Class
- T-cell engaging bispecific antibody (T-cell engager, TCE)
- Pathway
- Bridges CD19+ B cells with CD3+ T cells to drive T-cell-mediated B-cell killing/depletion
CD19 is a surface protein expressed on B cells across most stages of their development, from early precursors through mature forms, and it remains present on the majority of B-cell cancers, including many leukemias and lymphomas. CD3 is a signaling component of the T-cell receptor complex, found on nearly all T cells. A CD19 x CD3 bispecific antibody carries two distinct binding arms: one grips CD19 on a B cell, the other grips CD3 on a T cell. By binding both simultaneously, the molecule physically links the two cells together, forming an artificial immune synapse without requiring the T cell to recognize its usual antigen target. This forced contact activates the T cell, which then releases cytotoxic proteins that kill the attached B cell. Because activation does not depend on the T cell's native receptor specificity, this approach can recruit a broad portion of a patient's existing T-cell population against B cells bearing CD19, rather than relying on tumor-specific immune recognition developing naturally. This mechanism is relevant across B-cell malignancies and has also been explored in autoimmune conditions where depleting CD19-positive B cells, including those producing harmful autoantibodies, may reduce disease activity.
Related mechanisms
CD19 x CD3 drugs compared
4 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Blinatumomab | Amgen | bispecific antibody | Approved | Approved in Acute Lymphoblastic Leukemia; Phase 2 in Rheumatoid Arthritis; Phase 2 in Systemic Lupus Erythematosus |
| Surovatamig | AstraZeneca | bispecific antibody | Phase 3 | Phase 3 in Follicular Lymphoma; Phase 3 in Large B-Cell Lymphoma; Phase 2 in B-Cell Non-Hodgkin Lymphoma; Phase 1 in Rheumatoid Arthritis; Phase 1 in Systemic Lupus Erythematosus |
| CLN-978 | Cullinan Therapeutics Inc. | bispecific antibody | Phase 1 | Phase 1 in Rheumatoid Arthritis; Phase 1 in Systemic Lupus Erythematosus |
| XmAb657 | Xencor | bispecific antibody (T-cell engager) | Phase 1 | Phase 1 in Idiopathic Inflammatory Myopathies |